What the Options Market Tells Us About Bristol-Myers Squibb - Bristol-Myers Squibb (NYSE:BMY)

Core Insights - Financial giants are showing a bullish sentiment towards Bristol-Myers Squibb, with 44% of traders being bullish and 33% bearish in recent options trading [1] - Significant investors are targeting a price range of $45.0 to $57.5 for Bristol-Myers Squibb over the past three months [2] - The trading volume for Bristol-Myers Squibb stands at 3,924,289, with the stock price at $54.99, reflecting a 0.63% increase [10] Options Trading Analysis - A total of 9 unusual trades were identified, with 3 puts valued at $105,215 and 6 calls valued at $249,315 [1] - The largest options trades include a bearish call sweep at a strike price of $57.50, valued at $76.7K, and a bearish put sweep at the same strike price, valued at $50.2K [6] - The volume and open interest metrics indicate liquidity and investor interest in options trading for Bristol-Myers Squibb, particularly within the strike price range of $45.0 to $57.5 over the last 30 days [3] Company Overview - Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, with a strong emphasis on immuno-oncology [7] - Approximately 70% of Bristol-Myers Squibb's total sales are derived from the US market, indicating a higher dependence on the US compared to its peers [7] Analyst Ratings and Price Targets - Recent expert ratings suggest an average target price of $59.5 for Bristol-Myers Squibb, with individual targets ranging from $53 to $65 [9][10] - Analysts from various firms maintain differing ratings, with one upgrading to Buy and setting a price target of $65, while others maintain Neutral and Outperform ratings [10][11]